Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study has been completed.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00334152
First received: June 2, 2006
Last updated: May 31, 2012
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Condition | Intervention | Phase |
---|---|---|
Postoperative Nausea and Vomiting Nausea and Vomiting, Postoperative |
Drug: casopitant |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
Official Title: | A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis |
Resource links provided by NLM:
Further study details as provided by GlaxoSmithKline:
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00334152
Show 64 Study Locations
Show 64 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
More Information
No publications provided
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00334152 History of Changes |
Other Study ID Numbers: | NKT102552 |
Study First Received: | June 2, 2006 |
Last Updated: | May 31, 2012 |
Health Authority: | United States: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by GlaxoSmithKline:
ondansetron hydrochloride postoperative nausea and vomiting casopitant mesylate 5HT3 |
ZOFRAN NK-1 PONV antiemetics |
Additional relevant MeSH terms:
Nausea Vomiting Postoperative Nausea and Vomiting Signs and Symptoms, Digestive Signs and Symptoms Postoperative Complications Pathologic Processes Ondansetron Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Gastrointestinal Agents Antipruritics Dermatologic Agents Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Anti-Anxiety Agents |
ClinicalTrials.gov processed this record on October 16, 2012